haloperidol + ramelteon

Haloperidol + ramelteon is a combination of two pharmaceutical agents used together, primarily investigated for the management of sleep and circadian rhythm disturbances in patients with schizophrenia and potentially for delirium prevention or treatment. Haloperidol is a first-generation (typical) antipsychotic that acts as a potent antagonist at dopamine D2 receptors, reducing psychotic symptoms by inhibiting dopaminergic neurotransmission in the brain. Ramelteon is a melatonin receptor agonist with high affinity for MT1 and MT2 receptors, promoting sleep onset and regulating circadian rhythms without significant activity at other neuroreceptors. The combination may be considered when addressing both psychosis (via haloperidol) and associated sleep/circadian disruptions (via ramelteon), particularly in populations such as those with schizophrenia[1][2][4].